TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
ALMS

Alumis Inc

Healthcare · Biotechnology · —

7.80$ -0.6% vs. previous close Closing price · As of: Sep 18, 2026

Ownership

Ownership Structure

Who owns Alumis Inc (ALMS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 75.1% of the shares are freely tradable; institutional investors hold 99.9%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 99.9%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 0.6%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 75.1%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 7.3%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 129Mio.

Largest Shareholders

Institutions

Institutions ALMS
Name Stake (%) Shares Change (%) Date
BlackRock Inc 5.54 7,170,868 +57.0 03/31/2026
Deep Track Capital, LP 4.90 6,348,558 -6.3 06/30/2026
Samsara BioCapital, LLC 4.90 6,345,219 +0.0 06/30/2026
Foresite Capital Management V, LLC 4.56 5,896,995 +0.0 06/30/2026
venBio Partners LLC 3.50 4,528,408 +0.0 06/30/2026
Foresite Capital Management VI LLC 3.28 4,247,670 +0.0 06/30/2026
Vanguard Capital Management, LLC 3.12 4,032,266 +0.0 03/31/2026
Cormorant Asset Management, LLC 3.05 3,949,241 +8.6 03/31/2026
Nextech Invest, Ltd. 2.74 3,540,998 +0.0 06/30/2026
T. Rowe Price Associates, Inc. 2.54 3,286,753 +6,418.5 03/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Insider holdings

Insider holdings ALMS
Person Role Shares Value As of Type
Akkaraju Srinivas Director 7,235,809 56,439,310 $ Sep 8, 2026 indirect
Hardiman Roy C. Chief Business & Strategy Ofcr 207,746 1,620,419 $ Aug 3, 2026 direct
Drappa Jorn Chief Medical Officer 56,892 443,758 $ Aug 3, 2026 direct
Bradley Mark Christopher Chief Development Officer 48,533 378,557 $ Aug 3, 2026 direct
Goldstein David M Chief Scientific Officer 30,970 241,566 $ Aug 3, 2026 direct
Schroer John R. Chief Financial Officer 24,718 192,800 $ Aug 3, 2026 direct
Pangali Sanam Chief Legal Officer 9,747 76,027 $ Aug 3, 2026 direct

Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.

Insiders

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
Sep 8, 2026 Akkaraju Srinivas Director Buy 273,290 10.63 2,904,280
Sep 8, 2026 Akkaraju Srinivas Director Buy 273,291 10.63 2,904,291
Sep 8, 2026 Akkaraju Srinivas Director Sell 48,065 10.55 507,009
Sep 8, 2026 Akkaraju Srinivas Director Sell 48,066 10.55 507,019
Sep 4, 2026 Akkaraju Srinivas Director Buy 220,070 11.17 2,458,842
Aug 3, 2026 Pangali Sanam Chief Legal Officer Sell 1,364 26.37 35,969
Aug 3, 2026 Bradley Mark Christopher Chief Development Officer Sell 2,572 26.37 67,824
Aug 3, 2026 Drappa Jorn Chief Medical Officer Sell 2,447 26.37 64,527
Aug 3, 2026 Goldstein David M Chief Scientific Officer Sell 2,596 26.37 68,457
Aug 3, 2026 Schroer John R. Chief Financial Officer Sell 3,282 26.37 86,546
Aug 3, 2026 Hardiman Roy C. Chief Business & Strategy Ofcr Sell 2,692 26.37 70,988
Jul 6, 2026 Pangali Sanam Chief Legal Officer Sell 5,000 28.00 140,000
Jul 6, 2026 Pangali Sanam Chief Legal Officer Other 5,000 5.06 25,300

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?